链脲佐菌素诱导糖尿病小鼠模型的纵向在体特征:聚焦早期视网膜内层反应
该研究对链脲佐菌素(STZ)诱导的糖尿病视网膜病变(DR)小鼠模型进行了长达24周的纵向在体特征分析,发现视觉功能与视网膜结构在糖尿病早期即出现进行性损害,炎症可能是初始触发因素。阿柏西普或曲安奈德可改善炎症与胶质增生,提示该模型适用于研究早期DR的非血管性综合治疗。
要点
- STZ糖尿病小鼠在糖尿病发生后4周出现视力下降和视网膜变薄,18周出现对比敏感度丢失。
- 视网膜神经节细胞在4周、胆碱能无长突细胞在8周丢失,阿柏西普可进一步减少细胞丢失。
- 炎症(白细胞黏附在2周增加)可能是早期DR的初始触发因素,阿柏西普或曲安奈德可改善炎症与胶质增生。
核心结论
- STZ诱导糖尿病小鼠在早期即出现DR病理标志,炎症似乎是初始触发因素,进而导致功能和形态学视网膜改变。
- 该小鼠模型适用于研究治疗早期DR的新型综合性非血管疗法。
研究设计与样本
- 研究对STZ诱导糖尿病小鼠模型进行纵向在体特征分析,观察至糖尿病发生后24周。
- 检测方法包括视觉 acuity 与对比敏感度、ERG、SD-OCT、白细胞黏附及免疫组化。
- 给予阿柏西普或曲安奈德以研究其对上述病理过程的作用。
主要发现
- 视力下降始于糖尿病发生后4周,对比敏感度丢失始于18周,并随时间进行性下降。
- ERG振幅在6周后减低、OP潜伏期增加;SD-OCT显示视网膜从4周起变薄。
- 免疫组化显示视网膜神经节细胞在4周、胆碱能无长突细胞在8周丢失,阿柏西普给药后细胞丢失进一步减少。
- 黏附白细胞数量在2周后增加,微胶质细胞和大胶质细胞反应性从4周起增加。
- 阿柏西普或曲安奈德对炎症和胶质增生显示改善效果。
临床怎么用
- STZ糖尿病小鼠模型可用于研究早期DR的非血管性综合治疗。
- 阿柏西普或曲安奈德在模型中显示改善炎症和胶质增生的效果,但临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The goal of this study was to perform an extensive temporal characterization of the early pathologic processes in the streptozotocin (STZ)-induced diabetic retinopathy (DR) mouse model, beyond the vascular phenotype, and to investigate the potential of clinically relevant compounds in attenuating these processes. METHODS: Visual acuity and contrast sensitivity (CS) were studied in the mouse STZ model until 24 weeks postdiabetes onset. ERG, spectral domain optical coherence tomography (SD-OCT), leukostasis, and immunohistochemistry were applied to investigate neurodegeneration, inflammation, and gliosis during early-, mid- and late-phase diabetes. Aflibercept or triamcinolone acetonide (TAAC) was administered to investigate their efficacy on the aforementioned processes. RESULTS: Visual acuity and CS loss started at 4 and 18 weeks postdiabetes onset, respectively, and progressively declined over time. ERG amplitudes were diminished and OP latencies increased after 6 weeks, whereas SD-OCT revealed retinal thinning from 4 weeks postdiabetes. Immunohistochemical analyses linked these findings to retinal ganglion and cholinergic amacrine cell loss at 4 and 8 weeks postdiabetes onset, respectively, which was further decreased after aflibercept administration. The number of adherent leukocytes was augmented after 2 weeks, whereas increased micro- and macroglia reactivity was present from 4 weeks postdiabetes. Aflibercept or TAAC showed improved efficacy on inflammation and gliosis. CONCLUSIONS: STZ-induced diabetic mice developed early pathologic DR hallmarks, from which inflammation seemed the initial trigger, leading to further development of functional and morphologic retinal changes. These findings indicate that the mouse STZ model is suitable to study novel integrative non-vascular therapies to treat early DR.
引用
- Sergeys J, Etienne I, Van Hove I, et al. Longitudinal In Vivo Characterization of the Streptozotocin-Induced Diabetic Mouse Model: Focus on Early Inner Retinal Responses. Invest Ophthalmol Vis Sci. 2019. PMID: 30811545. doi:10.1167/iovs.18-25372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。